CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 179 filers reported holding CRISPR THERAPEUTICS AG in Q2 2018. The put-call ratio across all filers is 3.04 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $68,580,000 | -18.4% | 612,700 | +18.1% | 0.75% | -11.3% |
| Q2 2021 | $84,021,000 | +24.8% | 519,000 | -6.1% | 0.85% | +35.1% |
| Q1 2021 | $67,322,000 | -2.7% | 552,500 | +22.3% | 0.63% | +4.0% |
| Q4 2020 | $69,175,000 | +31.3% | 451,800 | -28.3% | 0.60% | -8.6% |
| Q3 2020 | $52,694,000 | +2.8% | 630,004 | -9.7% | 0.66% | -8.3% |
| Q2 2020 | $51,261,000 | +119.3% | 697,524 | +26.5% | 0.72% | +83.7% |
| Q1 2020 | $23,376,000 | -49.9% | 551,200 | -28.1% | 0.39% | -41.0% |
| Q4 2019 | $46,676,000 | +120.5% | 766,378 | +48.4% | 0.67% | +65.7% |
| Q3 2019 | $21,167,000 | -3.8% | 516,400 | +4.1% | 0.40% | +51.7% |
| Q3 2018 | $22,006,000 | -24.5% | 496,200 | 0.0% | 0.26% | -23.9% |
| Q2 2018 | $29,157,000 | +511.0% | 496,200 | +375.3% | 0.35% | +489.8% |
| Q1 2018 | $4,772,000 | -28.3% | 104,401 | -71.9% | 0.06% | -7.8% |
| Q3 2017 | $6,651,000 | +11.5% | 372,191 | 0.0% | 0.06% | +1.6% |
| Q2 2017 | $5,963,000 | -26.4% | 372,191 | 0.0% | 0.06% | -31.5% |
| Q1 2017 | $8,103,000 | +7.5% | 372,191 | 0.0% | 0.09% | -4.2% |
| Q4 2016 | $7,541,000 | – | 372,191 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |